AtriCure, Inc. - ATRC STOCK NEWS

AtriCure (Nasdaq: ATRC), a company specializing in surgical treatments for atrial fibrillation, left atrial appendage management, and post-operative pain management, has announced its participation in the Stifel 2024 Healthcare Conference. The company's management will engage in a fireside chat on Monday, November 18, 2024, at 9:10 am EST. A live audio webcast of the presentation will be accessible through the 'Investors' section of AtriCure's website.

AtriCure reported strong Q3 2024 financial results with worldwide revenue reaching $115.9 million, up 17.9% year-over-year. U.S. revenue grew 16.8% to $95.5 million, while international revenue increased 23.3% to $20.5 million. The company achieved 20% growth in U.S. open appendage management devices and generated positive cash flow of $16.3 million. Gross profit was $86.8 million with a 74.9% margin. The company updated its full-year 2024 revenue guidance to $459-462 million, representing 15-16% growth, and maintained its Adjusted EBITDA guidance of $26-29 million.

AtriCure (Nasdaq: ATRC), a company specializing in surgical treatments for atrial fibrillation, left atrial appendage management, and post-operative pain management, has announced its participation in the upcoming UBS Global Healthcare Conference. The company's management will engage in a fireside chat on Tuesday, November 12, 2024, at 5:00 pm Pacific Standard Time. A live audio webcast of the presentation will be accessible through the Investors section of AtriCure's website.

AtriCure, Inc. (Nasdaq: ATRC) has launched the cryoSPHERE MAX™ cryoablation probe, an upgraded device for Cryo Nerve Block™ therapy (cryoNB). The new probe features a larger 10 mm ball tip with 60% more surface area than previous models, enabling 50% reduced freeze times compared to the first-generation probe. Key improvements include:

- Reduced recommended ablation time to 60 seconds per targeted nerve
- Enhanced insulation and Nitrous Oxide gas utilization
- Improved tactile tissue feedback and real-time temperature monitoring
- Larger ice ball formation and greater heat extraction

These advancements aim to optimize efficiency, reduce total operative time, and improve gas utilization in post-operative pain management procedures.

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation, left atrial appendage management, and post-operative pain management, has announced it will release its third quarter 2024 financial results on Tuesday, October 29, 2024. The company will host an audio webcast at 4:30 p.m. Eastern Time on the same day to discuss the results.

Interested parties can register for the conference call online using the provided link. Registration is recommended more than 15 minutes before the call starts. Both live and replay versions of the audio webcast will be available on AtriCure's investor relations website.

AtriCure, Inc. (Nasdaq: ATRC) has received CE-Mark approval to sell the EnCompass® Clamp in European Union countries. This regulatory approval marks a significant expansion of AtriCure's product line internationally. The EnCompass Clamp, which received FDA 510(K) clearance and was launched in the United States in 2022, provides a simpler and faster approach to ablating the heart in open-chest procedures.

Key features of the EnCompass Clamp include:

• Ability to perform comprehensive epicardial ablation of the left atrium in minutes
• Parallel closure, uniform pressure, and custom power using Synergy radiofrequency (RF)
• Magnetic guide for easier placement and more efficient procedures
• Design that fits cardiac anatomy, supporting surgical ablation in procedures like CABG and AVR

AtriCure estimates approximately 400,000 cardiac surgeries occur annually in the European Union, representing a significant market opportunity for the EnCompass Clamp.

AtriCure, Inc. (Nasdaq: ATRC) has announced the successful treatment of the first patient with its newly 510(k) cleared AtriClip® FLEX-Mini™ device. This innovative product is now the smallest profile surgical LAA device available in the market, building upon AtriCure's proven AtriClip platform. The FLEX-Mini offers enhanced access and increased visibility for physicians, featuring a fully enclosed design with parallel beams for continuous closing force.

Key features of the AtriClip FLEX-Mini include:

• Low-profile design for improved visibility
• Ergonomic handle for single-handed placement
• Optimal pressure on atrial tissue

AtriCure, Inc. (Nasdaq: ATRC) has received an expanded CE-Mark indication for its AtriClip® devices in Europe. The devices are now indicated for use in patients at high risk of thromboembolism for whom left atrial appendage (LAA) exclusion is warranted. This expansion is based on substantial clinical evidence demonstrating a reduction in stroke events for patients receiving an AtriClip device.

The AtriClip family of devices are designed to exclude, electrically isolate, and eliminate the LAA during cardiac surgery. With over 550,000 patients treated worldwide, AtriCure has observed significant impact on patient care. The expanded indication confirms clinical evidence that strokes can be reduced in high-risk patients. Over 85 peer-reviewed studies involving more than 11,000 patients have been published on the safety and efficacy of AtriClip devices since 2007.

AtriCure, Inc. (Nasdaq: ATRC) reported strong Q2 2024 financial results, with worldwide revenue reaching $116.3 million, a 15.2% increase year-over-year. The company generated positive cash flow of $8.1 million in Q2. U.S. revenue grew by 12.5% to $95.5 million, while international revenue surged by 29.4% to $20.7 million. Despite revenue growth, AtriCure reported a loss from operations of $7.2 million and a net loss per share of $0.17. The company updated its full-year 2024 revenue guidance to $456-$461 million, reflecting approximately 15% growth at the midpoint. AtriCure expects full-year 2024 Adjusted EBITDA of $26-$29 million and an adjusted loss per share of $0.74-$0.82.